Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Nikolaus B. Wagner; Benjamin Weide; Mirko Gries; Maike Reith; Kathrin Tarnanidis; Valerie Schuermans; Charlotte Kemper; Coretta Kehrel; Anne Funder; Ramtin Lichtenberger; Antje Sucker; Esther Herpel; Tim Holland-Letz; Dirk Schadendorf; Claus Garbe; Viktor Umansky; Jochen Utikal; Christoffer Gebhardt

doi:10.1186/s40425-019-0828-1

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

XML

Research Article

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Wagner NB, Weide B, Gries M, et al

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Journal for ImmunoTherapy of Cancer 2019;7:343. doi: 10.1186/s40425-019-0828-1

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password